Safety Study of Zimura™in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD
Status:
Completed
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the safety of intravitreal (IVT) Zimura® administered in
combination with anti-VEGF Therapy (AVASTIN®, EYLEA®, OR LUCENTIS®) in anti-VEGF treatment
experienced subjects with neovascular age-related macular degeneration (AMD)